VIA Pharmaceuticals (VIAP) 8-K Corautus Genetics Inc. Announces FDA Approval for Commencement of Its

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2004

CORAUTUS GENETICS INC.

(Exact Name Of Registrant As Specified In Charter)

Delaware	0-27264	33-0687976
(State of Incorporation)	(Commission File No.)	(I.R.S. Employer Identification No.)

75 Fifth Street, Suite 313

Atlanta, Georgia 30308

(Address of principal executive offices, including zip code)

(404) 526-6200

(Registrant’s telephone number, including area code)

Item 5. Other Events.

On July 15, 2004, Corautus Genetics Inc. issued a press release, attached hereto as Exhibit 99.1, announcing that the U.S. Food and Drug Administration had approved the commencement of Corautus’ Phase IIB clinical trial for treatment of severe cardiovascular disease.

Item 7. Financial Statements and Exhibits

(c)

Exhibit Number	Description
99.1	Press Release dated July 15, 2004.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Corautus Genetics Inc.
Date: July 15, 2004	By:	/s/ Jack W. Callicutt
		Jack W. Callicutt
		Vice President - Finance and Administration, Chief Accounting Officer and Assistant Secretary